Loading
Everything OnCo dates to 1971: 14 entries, 7 landmarks, 2 approvals, 2 papers and 1 company founded. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
14 dated entries in OnCo fall in 1971: 7 landmarks, 2 approvals, 2 papers, 1 company founded, 1 journal founded and 1 technology.
Of those, 14 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Palliative treatment of advanced carcinoma of the breast or endometrium
Palliative treatment of advanced endometrial and breast cancer (megestrol)
The publication year on key paper records.
Herbst AL, Ulfelder H, Poskanzer DC. New England Journal of Medicine.
Knudson AG. Proceedings of the National Academy of Sciences.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Vaginal cancer. Herbst and colleagues (NEJM 1971) report the association; DES is withdrawn for pregnancy the same year.
Low-risk neuroblastoma (INRG very low and low risk, including stage MS)
Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)
Retinoblastoma. Statistical analysis of hereditary vs sporadic retinoblastoma predicts tumour-suppressor genes.
Endometrial cancer
Advanced or recurrent endometrial cancer
Neuroblastoma (paediatric)
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Fleurus
The founded year on journal records.
Oxford University Press